Get the Stockscreener App
1.3207
0.76%
0.0007
Scynexis Inc stock is traded at $1.3207, with a volume of 35,900.
It is up +0.76% in the last 24 hours and down -7.64% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$1.32
Open:
$1.3
24h Volume:
35,900
Relative Volume:
0.26
Market Cap:
$49.97M
Revenue:
$135.87M
Net Income/Loss:
$72.20M
P/E Ratio:
1.5723
EPS:
0.84
Net Cash Flow:
$45.09M
1W Performance:
-5.00%
1M Performance:
-7.64%
6M Performance:
-24.86%
1Y Performance:
-29.26%
1-Day Range:
$1.30
$1.33
1-Week Range:
$1.30
$1.42
52-Week Range:
$1.26
$3.07
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. In - GuruFocus.com
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving AverageShould You Sell? - MarketBeat
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200 Day Moving AverageTime to Sell? - MarketBeat
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - The Manila Times
SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average of $1.82 - MarketBeat
CRISPR Therapeutics: Prepare To Be Bored (NASDAQ:CRSP) - Seeking Alpha
Potential Price Increase for Synopsys, Inc. (SNPS) After Recent Insider Activity - Knox Daily
Scynexis CEO acquires $27,400 in company stock By Investing.com - Investing.com Canada
Syncona Advances Share Buyback, Bolsters Treasury Shares - TipRanks
Xero buys South African firm for $115m in 'departure' - New Zealand Herald
SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Buys 20,000 Shares - MarketBeat
Scynexis CEO acquires $27,400 in company stock - Investing.com
Synectics says trading is 'significantly ahead' of previous guidance - Proactive Investors USA
Better than expected profits forecast for security tech company - The Business Desk
Synopsys Inc. stock rises Friday, still underperforms market - MarketWatch
SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average of $1.83 - MarketBeat
SCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook - TipRanks
SCYNEXIS (NASDAQ:SCYX) Shares Cross Below 200-Day Moving Average of $1.84 - MarketBeat
Financial Fitness Check: Examining Scynexis Inc (SCYX)’s Key Ratios - The Dwinnex
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
SCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to Sell - Defense World
SCYNEXIS (NASDAQ:SCYX) Downgraded to "Sell" at StockNews.com - MarketBeat
SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Scynexis: Q2 Earnings Snapshot - San Antonio Express-News
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update - wallstreet:online
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt? - Simply Wall St
Acadian Asset Management LLC Purchases 21,700 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
SCYNEXIS secures $10 million milestone from GSK - Investing.com India
SCYNEXIS secures $10 million milestone from GSK By Investing.com - Investing.com Canada
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports - StockTitan
3 Stocks Under $10 With the Potential for Massive Gains - InvestorPlace
Empowered Funds LLC Has $130,000 Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
3 Dirt-Cheap Drug Developers With Blockbuster Potential - InvestorPlace
SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update - Quantisnow
A Look Into Healthcare Sector Value Stocks - Quantisnow
Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US ... - Yahoo Movies UK
SCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five years - Yahoo New Zealand News
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below Fifty Day Moving Average of $2.01 - Defense World
SCYNEXIS (NASDAQ:SCYX) Share Price Crosses Below Fifty Day Moving Average of $2.01 - MarketBeat
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Lifestyle Singapore
SCYNEXIS Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders - Quantisnow
Ileal Sodium/Bile Acid Cotransporter Market 2030 | CJ HealthCare Corp, GlaxoSmithKline Plc, Scynexis Inc, Takeda ... - PrimePair
SCYNEXIS shareholders approve key proposals at annual meeting By Investing.com - Investing.com Australia
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):